Alexander C. Ford

List of Publications by Citations

466 papers	20,268 citations	76 h-index	134 g-index
547 ext. papers	25,427 ext. citations	8.1 avg, IF	7.62 L-index

#	Paper	IF	Citations
466	Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. *Clinical Gastroenterology and Hepatology*, **2012**, 10, 712-721.e4	6.9	1230
465	The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. *Gut*, **2010**, 59, 325-32	19.2	472
464	Prevalence of, and risk factors for, chronic idiopathic constipation in the community: systematic review and meta-analysis. *American Journal of Gastroenterology*, **2011**, 106, 1582-91; quiz 1581, 1592	0.7	464
463	Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. *American Journal of Gastroenterology*, **2014**, 109, 1547-61; quiz 1546, 1562	0.7	447
462	Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. *American Journal of Gastroenterology*, **2011**, 106, 644-59, quiz 660	0.7	437
461	Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. *Gut*, **2009**, 58, 367-78	19.2	404
460	American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. *American Journal of Gastroenterology*, **2014**, 109 Suppl 1, S2-26; quiz S27	0.7	393
459	Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. *American Journal of Gastroenterology*, **2011**, 106, 661-73	0.7	390
458	Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. *BMJ, The*, **2014**, 348, g3174	5.9	380
457	Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. *BMJ, The*, **2008**, 337, a2313	5.9	368
456	Probiotic Bifidobacterium longum NCC3001 Reduces Depression Scores and Alters Brain Activity: A Pilot Study in Patients With Irritable Bowel Syndrome. *Gastroenterology*, **2017**, 153, 448-459.e8	13.3	358
455	Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis. *American Journal of Gastroenterology*, **2012**, 107, 1474-82	0.7	357
454	Irritable Bowel Syndrome. *New England Journal of Medicine*, **2017**, 376, 2566-2578	59.2	291
453	Functional Dyspepsia. *New England Journal of Medicine*, **2015**, 373, 1853-63	59.2	268
452	Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysis. *American Journal of Gastroenterology*, **2014**, 109, 1350-65; quiz 1366	0.7	262
451	Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. *Clinical Gastroenterology and Hepatology*, **2009**, 7, 1279-86	6.9	260
450	Global prevalence of, and risk factors for, uninvestigated dyspepsia: a meta-analysis. *Gut*, **2015**, 64, 1049-57	15.2	253

449	Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. *Alimentary Pharmacology and Therapeutics*, **2018**, 48, 1044-1060	6.1	248
448	Opportunistic infections with anti-tumor necrosis factor-α therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials. *American Journal of Gastroenterology*, **2013**, 108, 1268-76	0.7	247
447	Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: systematic review and meta-analysis. *Gut*, **2011**, 60, 209-18	19.2	240
446	Effect of gender on prevalence of irritable bowel syndrome in the community: systematic review and meta-analysis. *American Journal of Gastroenterology*, **2012**, 107, 991-1000	0.7	232
445	Pathophysiology of irritable bowel syndrome. *The Lancet Gastroenterology and Hepatology*, **2016**, 1, 133-146	18.6	224
444	Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. *American Journal of Gastroenterology*, **2011**, 106, 590-9; quiz 600	0.7	212
443	Systematic review with meta-analysis: the efficacy of probiotics in inflammatory bowel disease. *Alimentary Pharmacology and Therapeutics*, **2017**, 46, 389-400	6.1	206
442	The effect of fiber supplementation on irritable bowel syndrome: a systematic review and meta-analysis. *American Journal of Gastroenterology*, **2014**, 109, 1367-74	0.7	202
441	Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. *American Journal of Gastroenterology*, **2009**, 104, 1831-43; quiz 1844	0.7	198
440	Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis. *Gut*, **2018**, 67, 430-440	19.2	197
439	Effect of Antidepressants and Psychological Therapies in Irritable Bowel Syndrome: An Updated Systematic Review and Meta-Analysis. *American Journal of Gastroenterology*, **2019**, 114, 21-39	0.7	185
438	Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis. *American Journal of Gastroenterology*, **2011**, 106, 630-42	0.7	183
437	Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. *American Journal of Gastroenterology*, **2011**, 106, 601-16	0.7	176
436	A Systematic Review and Meta-Analysis Evaluating the Efficacy of a Gluten-Free Diet and a Low FODMAPs Diet in Treating Symptoms of Irritable Bowel Syndrome. *American Journal of Gastroenterology*, **2018**, 113, 1290-1300	0.7	173
435	American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome. *American Journal of Gastroenterology*, **2018**, 113, 1-18	0.7	170
434	Systematic review: the effects of fibre in the management of chronic idiopathic constipation. *Alimentary Pharmacology and Therapeutics*, **2011**, 33, 895-901	6.1	161
433	Cough in the community: a cross sectional survey and the relationship to gastrointestinal symptoms. *Thorax*, **2006**, 61, 975-9	7.3	156
432	Neuromodulators for Functional Gastrointestinal Disorders (Disorders of Gut-Brain Interaction): A Rome Foundation Working Team Report. *Gastroenterology*, **2018**, 154, 1140-1171.e1	13.3	155

431	Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of irritable bowel syndrome: systematic review and meta-analysis. *Archives of Internal Medicine*, **2009**, 169, 651-8		155
430	Effect of psychological therapy on disease activity, psychological comorbidity, and quality of life in inflammatory bowel disease: a systematic review and meta-analysis. *The Lancet Gastroenterology and Hepatology*, **2017**, 2, 189-199	18.8	152
429	Irritable bowel syndrome: a 10-yr natural history of symptoms and factors that influence consultation behavior. *American Journal of Gastroenterology*, **2008**, 103, 1229-39; quiz 1240	0.7	150
428	Meta-analysis: factors affecting placebo response rate in the irritable bowel syndrome. *Alimentary Pharmacology and Therapeutics*, **2010**, 32, 144-58	6.1	149
427	Bi-directionality of Brain-Gut Interactions in Patients With Inflammatory Bowel Disease. *Gastroenterology*, **2018**, 154, 1635-1646.e3	13.3	148
426	Efficacy of 5-aminosalicylates in Crohn's disease: systematic review and meta-analysis. *American Journal of Gastroenterology*, **2011**, 106, 617-29	0.7	147
425	Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: a meta-analysis. *Journal of Crohnls and Colitis*, **2013**, 7, 853-67	1.5	142
424	Gastroparesis. *Nature Reviews Disease Primers*, **2018**, 4, 41	51.1	138
423	Mucosal inflammation as a potential etiological factor in irritable bowel syndrome: a systematic review. *Journal of Gastroenterology*, **2011**, 46, 421-31	6.9	134
422	Systematic review and meta-analysis of the prevalence of irritable bowel syndrome in individuals with dyspepsia. *Clinical Gastroenterology and Hepatology*, **2010**, 8, 401-9	6.9	134
421	Ethnicity, gender, and socioeconomic status as risk factors for esophagitis and Barrett's esophagus. *American Journal of Epidemiology*, **2005**, 162, 454-60	3.8	128
420	Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis. *American Journal of Gastroenterology*, **2004**, 99, 1833-55	0.7	126
419	Validation of the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care. *Gastroenterology*, **2013**, 145, 1262-70.e1	13.3	124
418	What is the prevalence of clinically significant endoscopic findings in subjects with dyspepsia? Systematic review and meta-analysis. *Clinical Gastroenterology and Hepatology*, **2010**, 8, 830-7, 837.e1-2	6.9	121
417	Irritable bowel syndrome. *Lancet, The*, **2020**, 396, 1675-1688	40	113
416	Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-□therapy in inflammatory bowel disease. *Alimentary Pharmacology and Therapeutics*, **2014**, 39, 447-58	6.1	112
415	Systematic review with meta-analysis: the prevalence of bile acid malabsorption in the irritable bowel syndrome with diarrhoea. *Alimentary Pharmacology and Therapeutics*, **2015**, 42, 3-11	6.1	111
414	Prevalence of irritable bowel syndrome-type symptoms in patients with celiac disease: a meta-analysis. *Clinical Gastroenterology and Hepatology*, **2013**, 11, 359-65.e1	6.9	108

413	Diagnostic utility of alarm features for colorectal cancer: systematic review and meta-analysis. *Gut*, **2008**, 57, 1545-53	19.2	107
412	Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. *The Lancet Gastroenterology and Hepatology*, **2020**, 5, 908-917	18.8	107
411	Chronic constipation. *Nature Reviews Disease Primers*, **2017**, 3, 17095	51.1	106
410	Efficacy of oral vs. topical, or combined oral and topical 5-aminosalicylates, in Ulcerative Colitis: systematic review and meta-analysis. *American Journal of Gastroenterology*, **2012**, 107, 167-76; author reply 177	0.7	106
409	Systematic review with meta-analysis: the adverse effects of tobacco smoking on the natural history of Crohn's disease. *Alimentary Pharmacology and Therapeutics*, **2016**, 43, 549-61	6.1	102
408	Ulcerative colitis. *BMJ, The*, **2013**, 346, f432	5.9	99
407	Epidemiology of Helicobacter pylori infection and public health implications. *Helicobacter*, **2010**, 15 Suppl 1, 1-6	4.9	97
406	Efficacy of psychotropic drugs in functional dyspepsia: systematic review and meta-analysis. *Gut*, **2017**, 66, 411-420	19.2	96
405	Population screening and treatment of Helicobacter pylori infection. *Nature Reviews Gastroenterology and Hepatology*, **2017**, 14, 230-240	24.2	96
404	Systematic review with meta-analysis: efficacy of faecal microbiota transplantation for the treatment of irritable bowel syndrome. *Alimentary Pharmacology and Therapeutics*, **2019**, 50, 240-248	6.1	86
403	Adverse events with bismuth salts for Helicobacter pylori eradication: systematic review and meta-analysis. *World Journal of Gastroenterology*, **2008**, 14, 7361-70	5.6	85
402	Helicobacter pylori "test and treat" or endoscopy for managing dyspepsia: an individual patient data meta-analysis. *Gastroenterology*, **2005**, 128, 1838-44	13.3	85
401	Poor Correlation Between Clinical Disease Activity and Mucosal Inflammation, and the Role of Psychological Comorbidity, in Inflammatory Bowel Disease. *American Journal of Gastroenterology*, **2016**, 111, 541-51	0.7	84
400	Faecal microbiota transplantation for Clostridium difficile-associated diarrhoea: a systematic review of randomised controlled trials. *Medical Journal of Australia*, **2017**, 207, 166-172	4	83
399	Functional dyspepsia. *Lancet, The*, **2020**, 396, 1689-1702	40	83
398	5-aminosalicylates prevent relapse of Crohn's disease after surgically induced remission: systematic review and meta-analysis. *American Journal of Gastroenterology*, **2011**, 106, 413-20	0.7	82
397	eradication therapy to prevent gastric cancer: systematic review and meta-analysis. *Gut*, **2020**, 69, 2113-2121	19.1	81
396	Anxiety and Depression Increase in a Stepwise Manner in Parallel With Multiple FGIDs and Symptom Severity and Frequency. *American Journal of Gastroenterology*, **2015**, 110, 1038-48	0.7	81

395	Optimum duration of regimens for Helicobacter pylori eradication. *The Cochrane Library*, **2013**, CD008337	7.2	80
394	Initial poor quality of life and new onset of dyspepsia: results from a longitudinal 10-year follow-up study. *Gut*, **2007**, 56, 321-7	19.2	80
393	Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: systematic review and meta-analysis. *American Journal of Gastroenterology*, **2013**, 108, 1566-74; quiz 1575	0.7	79
392	World Gastroenterology Organisation Global Guidelines: GERD Global Perspective on Gastroesophageal Reflux Disease. *Journal of Clinical Gastroenterology*, **2017**, 51, 467-478	3	78
391	Characteristics of functional bowel disorder patients: a cross-sectional survey using the Rome III criteria. *Alimentary Pharmacology and Therapeutics*, **2014**, 39, 312-21	6.1	76
390	Systematic review: The epidemiology of the hepatobiliary manifestations in patients with inflammatory bowel disease. *Alimentary Pharmacology and Therapeutics*, **2014**, 40, 3-15	6.1	76
389	Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: a large single centre experience. *Journal of Crohnls and Colitis*, **2012**, 6, 143-53	1.5	75
388	Global burden of irritable bowel syndrome: trends, predictions and risk factors. *Nature Reviews Gastroenterology and Hepatology*, **2020**, 17, 473-486	24.2	75
387	Clinical and epidemiological differences in functional dyspepsia between the East and the West. *Neurogastroenterology and Motility*, **2016**, 28, 167-74	4	72
386	Efficacy of Secretagogues in Patients With Irritable Bowel Syndrome With Constipation: Systematic Review and Network Meta-analysis. *Gastroenterology*, **2018**, 155, 1753-1763	13.3	72
385	Gastro-oesophageal reflux is more prevalent in Western dyspeptics: a prospective comparison of British and South-East Asian patients with dyspepsia. *Alimentary Pharmacology and Therapeutics*, **2005**, 21, 1483-90	6.1	71
384	Screening for Celiac Disease in Irritable Bowel Syndrome: An Updated Systematic Review and Meta-analysis. *American Journal of Gastroenterology*, **2017**, 112, 65-76	0.7	70
383	Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. *Cochrane Database of Systematic Reviews*, **2006**, CD003840		69
382	The overlap of atopy and functional gastrointestinal disorders among 23,471 patients in primary care. *Alimentary Pharmacology and Therapeutics*, **2014**, 40, 382-91	6.1	68
381	Will the history and physical examination help establish that irritable bowel syndrome is causing this patient's lower gastrointestinal tract symptoms?. *JAMA - Journal of the American Medical Association*, **2008**, 300, 1793-805	27.4	68
380	Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis. *Gut*, **2020**, 69, 74-82	19.2	68
379	Prevalence of, and predictors of, bile acid malabsorption in outpatients with chronic diarrhea. *Neurogastroenterology and Motility*, **2012**, 24, 983-e538	4	67
378	The influence of the brain-gut axis in inflammatory bowel disease and possible implications for treatment. *The Lancet Gastroenterology and Hepatology*, **2019**, 4, 632-642	18.8	66

377	Safety of Adding Oats to a Gluten-Free Diet for Patients With Celiac Disease: Systematic Review and Meta-analysis of Clinical and Observational Studies. *Gastroenterology*, **2017**, 153, 395-409.e3	13.3	62
376	Helicobacter pylori test and treat versus proton pump inhibitor in initial management of dyspepsia in primary care: multicentre randomised controlled trial (MRC-CUBE trial). *BMJ, The*, **2008**, 336, 651-4	5.9	61
375	Immunologic distribution of an organic anion transport protein in rat liver and kidney. *American Journal of Physiology - Renal Physiology*, **1996**, 271, G231-8	5.1	61
374	High Prevalence of Idiopathic Bile Acid Diarrhea Among Patients With Diarrhea-Predominant Irritable Bowel Syndrome Based on Rome III Criteria. *Clinical Gastroenterology and Hepatology*, **2015**, 13, 1650-5.e2	6.9	60
373	The Rome III criteria for the diagnosis of functional dyspepsia in secondary care are not superior to previous definitions. *Gastroenterology*, **2014**, 146, 932-40; quiz e14-5	13.3	60
372	Prevalence of uninvestigated dyspepsia 8 years after a large waterborne outbreak of bacterial dysentery: a cohort study. *Gastroenterology*, **2010**, 138, 1727-36; quiz e12	13.3	60
371	Irritable bowel syndrome. *BMJ, The*, **2012**, 345, e5836	5.9	59
370	Prevalence of gastro-esophageal reflux-type symptoms in individuals with irritable bowel syndrome in the community: a meta-analysis. *American Journal of Gastroenterology*, **2012**, 107, 1793-801; quiz 1802	0.7	58
369	Meta-analysis: Coeliac disease and hypertransaminasaemia. *Alimentary Pharmacology and Therapeutics*, **2011**, 34, 33-40	6.1	58
368	Who consults with dyspepsia? Results from a longitudinal 10-yr follow-up study. *American Journal of Gastroenterology*, **2007**, 102, 957-65	0.7	58
367	Efficacy of soluble fibre, antispasmodic drugs, and gut-brain neuromodulators in irritable bowel syndrome: a systematic review and network meta-analysis. *The Lancet Gastroenterology and Hepatology*, **2020**, 5, 117-131	18.8	58
366	Negative Effects on Psychological Health and Quality of Life of Genuine Irritable Bowel Syndrome-type Symptoms in Patients With Inflammatory Bowel Disease. *Clinical Gastroenterology and Hepatology*, **2017**, 15, 376-384.e5	6.9	57
365	Systematic review: prognostic tests of paracetamol-induced acute liver failure. *Alimentary Pharmacology and Therapeutics*, **2010**, 31, 1064-76	6.1	57
364	The Short-Form Leeds Dyspepsia Questionnaire validation study. *Alimentary Pharmacology and Therapeutics*, **2007**, 25, 477-86	6.1	57
363	Initial management strategies for dyspepsia. *Cochrane Database of Systematic Reviews*, **2005**, CD001961		56
362	Functional gastrointestinal disorders: advances in understanding and management. *Lancet, The*, **2020**, 396, 1664-1674	40	56
361	Systematic review with meta-analysis: the accuracy of diagnosing irritable bowel syndrome with symptoms, biomarkers and/or psychological markers. *Alimentary Pharmacology and Therapeutics*, **2015**, 42, 491-503	6.1	54
360	Efficacy of psychological therapies for irritable bowel syndrome: systematic review and network meta-analysis. *Gut*, **2020**, 69, 1441-1451	19.2	53

359	Systematic review and meta-analysis: opportunistic infections and malignancies during treatment with anti-integrin antibodies in inflammatory bowel disease. *Alimentary Pharmacology and Therapeutics*, **2015**, 41, 1227-36	6.1	51
358	Effect of dyspepsia on survival: a longitudinal 10-year follow-up study. *American Journal of Gastroenterology*, **2012**, 107, 912-21	0.7	51
357	Incidence of Bloodstream Infections, Length of Hospital Stay, and Survival in Patients With Recurrent Clostridioides difficile Infection Treated With Fecal Microbiota Transplantation or Antibiotics: A Prospective Cohort Study. *Annals of Internal Medicine*, **2019**, 171, 695-702	8	50
356	A community screening program for Helicobacter pylori saves money: 10-year follow-up of a randomized controlled trial. *Gastroenterology*, **2005**, 129, 1910-7	13.3	48
355	Once-daily dosing vs. conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysis. *American Journal of Gastroenterology*, **2011**, 106, 2070-7; quiz 2078	0.7	47
354	Prevalence of organic disease at colonoscopy in patients with symptoms compatible with irritable bowel syndrome: cross-sectional survey. *Scandinavian Journal of Gastroenterology*, **2015**, 50, 816-23	2.4	46
353	Irritable Bowel Syndrome and Microscopic Colitis: A Systematic Review and Meta-analysis. *Clinical Gastroenterology and Hepatology*, **2016**, 14, 659-68.e1; quiz e54-5	6.9	45
352	De novo design of covalently constrained mesosize protein scaffolds with unique tertiary structures. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, 10852-10857	11.5	44
351	Helicobacter pylori eradication for the prevention of gastric neoplasia. *Cochrane Database of Systematic Reviews*, **2015**, CD005583		43
350	Efficacy of drugs in chronic idiopathic constipation: a systematic review and network meta-analysis. *The Lancet Gastroenterology and Hepatology*, **2019**, 4, 831-844	18.8	42
349	Longitudinal impact of IBS-type symptoms on disease activity, healthcare utilization, psychological health, and quality of life in inflammatory bowel disease. *American Journal of Gastroenterology*, **2018**, 113, 702-712	0.7	42
348	Systematic review with meta-analysis: the effect of tobacco smoking on the natural history of ulcerative colitis. *Alimentary Pharmacology and Therapeutics*, **2016**, 44, 117-26	6.1	42
347	Efficacy of topical 5-aminosalicylates in preventing relapse of quiescent ulcerative colitis: a meta-analysis. *Clinical Gastroenterology and Hepatology*, **2012**, 10, 513-9	6.9	42
346	Meta-analysis: yield of diagnostic tests for coeliac disease in dyspepsia. *Alimentary Pharmacology and Therapeutics*, **2009**, 30, 28-36	6.1	42
345	Fluctuation of gastrointestinal symptoms in the community: a 10-year longitudinal follow-up study. *Alimentary Pharmacology and Therapeutics*, **2008**, 28, 1013-20	6.1	42
344	Irritable bowel syndrome is significantly associated with somatisation in 840 patients, which may drive bloating. *Alimentary Pharmacology and Therapeutics*, **2015**, 41, 449-58	6.1	41
343	Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systematic review and meta-analysis. *The Lancet Gastroenterology and Hepatology*, **2021**, 6, 359-370	18.8	41
342	Chronic idiopathic constipation in adults: epidemiology, pathophysiology, diagnosis and clinical management. *Medical Journal of Australia*, **2018**, 209, 86-91	4	40

341	Association between constipation and colorectal cancer: systematic review and meta-analysis of observational studies. *American Journal of Gastroenterology*, **2013**, 108, 894-903; quiz 904	0.7	40
340	Errors in the conduct of systematic reviews of pharmacological interventions for irritable bowel syndrome. *American Journal of Gastroenterology*, **2010**, 105, 280-8	0.7	40
339	Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: systematic review and network meta-analysis. *Gut*, **2019**, 68, 434-444	19.2	39
338	The Effect of Dietary Intervention on Irritable Bowel Syndrome: A Systematic Review. *Clinical and Translational Gastroenterology*, **2015**, 6, e107	4.2	37
337	NICE clinical guideline (CG152): the management of Crohn's disease in adults, children and young people. *Alimentary Pharmacology and Therapeutics*, **2013**, 37, 195-203	6.1	37
336	Systematic review: granulocyte/monocyte adsorptive apheresis for ulcerative colitis. *Alimentary Pharmacology and Therapeutics*, **2010**, 32, 1297-306	6.1	37
335	Meta-analysis: Helicobacter pylori'test and treat' compared with empirical acid suppression for managing dyspepsia. *Alimentary Pharmacology and Therapeutics*, **2008**, 28, 534-44	6.1	37
334	Systematic Review and Meta-analysis: Optimal Salvage Therapy in Acute Severe Ulcerative Colitis. *Inflammatory Bowel Diseases*, **2019**, 25, 1169-1186	4.5	37
333	Meta-analysis: the epidemiology of noncardiac chest pain in the community. *Alimentary Pharmacology and Therapeutics*, **2011**, 34, 172-80	6.1	35
332	Epidemiological, Clinical, and Psychological Characteristics of Individuals with Self-reported Irritable Bowel Syndrome Based on the Rome IV vs Rome III Criteria. *Clinical Gastroenterology and Hepatology*, **2020**, 18, 392-398.e2	6.9	35
331	Diagnosis of IBS: symptoms, symptom-based criteria, biomarkers or 'psychomarkers'?. *Nature Reviews Gastroenterology and Hepatology*, **2014**, 11, 683-91	24.2	34
330	Eradication therapy for peptic ulcer disease in Helicobacter pylori-positive people. *The Cochrane Library*, **2016**, 4, CD003840	5.2	33
329	Relative Efficacy of Tegaserod in a Systematic Review and Network Meta-analysis of Licensed Therapies for Irritable Bowel Syndrome With Constipation. *Clinical Gastroenterology and Hepatology*, **2020**, 18, 1238-1239.e1	6.9	33
328	Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease. *European Journal of Gastroenterology and Hepatology*, **2009**, 21, 71-5	2.2	32
327	Development and validation of a scoring system to identify patients with microscopic colitis. *Clinical Gastroenterology and Hepatology*, **2015**, 13, 1125-31	6.9	31
326	British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. *Gut*, **2021**, 70, 1214-1240	19.2	31
325	Efficacy of tumour necrosis factor antagonists on remission, colectomy and hospitalisations in ulcerative colitis: Meta-analysis of placebo-controlled trials. *Digestive and Liver Disease*, **2015**, 47, 356-64	3.3	29
324	Prevalence of functional gastrointestinal disorders among consecutive new patient referrals to a gastroenterology clinic. *Frontline Gastroenterology*, **2014**, 5, 266-271	2.6	29

323	Current guidelines for dyspepsia management. *Digestive Diseases*, **2008**, 26, 225-30	3.2	29
322	Prevalence of irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease in remission: a systematic review and meta-analysis. *The Lancet Gastroenterology and Hepatology*, **2020**, 5, 1053-1062	18.8	29
321	Costs of care for Crohn's disease following the introduction of infliximab: a single-centre UK experience. *Alimentary Pharmacology and Therapeutics*, **2010**, 32, 1357-63	6.1	28
320	Mycophenolate mofetil therapy for refractory inflammatory bowel disease. *Inflammatory Bowel Diseases*, **2007**, 13, 1488-92	4.5	28
319	Diagnosis: Rome IV criteria for FGIDs - an improvement or more of the same?. *Nature Reviews Gastroenterology and Hepatology*, **2016**, 13, 501-2	24.2	27
318	Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience. *Scandinavian Journal of Gastroenterology*, **2018**, 53, 700-707	2.4	26
317	Effect of sibling number in the household and birth order on prevalence of Helicobacter pylori: a cross-sectional study. *International Journal of Epidemiology*, **2007**, 36, 1327-33	7.8	26
316	Enhancing Diagnostic Performance of Symptom-Based Criteria for Irritable Bowel Syndrome by Additional History and Limited Diagnostic Evaluation. *American Journal of Gastroenterology*, **2016**, 111, 1446-1454	0.7	26
315	Cyclic vomiting syndrome is a prevalent and under-recognized condition in the gastroenterology outpatient clinic. *Neurogastroenterology and Motility*, **2018**, 30, e13174	4	25
314	The relationship between different information sources and disease-related patient knowledge and anxiety in patients with inflammatory bowel disease. *Alimentary Pharmacology and Therapeutics*, **2017**, 45, 63-74	6.1	25
313	Epidemiology and outcomes of gastroparesis, as documented in general practice records, in the United Kingdom. *Gut*, **2021**, 70, 644-653	19.2	25
312	Increased prevalence of autoimmune diseases in functional gastrointestinal disorders: case-control study of 23471 primary care patients. *Alimentary Pharmacology and Therapeutics*, **2014**, 40, 827-34	6.1	24
311	IBS-like symptoms in patients with ulcerative colitis. *Clinical and Experimental Gastroenterology*, **2015**, 8, 101-9	3.1	24
310	Treatment of irritable bowel syndrome: beyond fiber and antispasmodic agents. *Therapeutic Advances in Gastroenterology*, **2011**, 4, 115-27	4.7	24
309	Antidepressants in inflammatory bowel disease. *Nature Reviews Gastroenterology and Hepatology*, **2020**, 17, 184-192	24.2	23
308	Ipilimumab-induced colitis: experience from a tertiary referral center. *Therapeutic Advances in Gastroenterology*, **2016**, 9, 457-62	4.7	23
307	Helicobacter pylori eradication for the prevention of gastric neoplasia. *The Cochrane Library*, **2020**, 7, CD005583	5.2	21
306	Placebo response rate in clinical trials of fistulizing Crohn's disease: systematic review and meta-analysis. *Clinical Gastroenterology and Hepatology*, **2014**, 12, 1981-90	6.9	21

305	Prevalence of Dyspepsia in Individuals With Gastroesophageal Reflux-Type Symptoms in the Community: A Systematic Review and Meta-analysis. *Clinical Gastroenterology and Hepatology*, **2018**, 16, 39-48.e1	6.9	21
304	Low-dose imipramine for refractory functional dyspepsia: a randomised, double-blind, placebo-controlled trial. *The Lancet Gastroenterology and Hepatology*, **2018**, 3, 837-844	18.8	21
303	Macroscopic findings, incidence and characteristics of microscopic colitis in a large cohort of patients from the United Kingdom. *Scandinavian Journal of Gastroenterology*, **2017**, 52, 988-994	2.4	20
302	Anxiety-related factors associated with symptom severity in irritable bowel syndrome. *Neurogastroenterology and Motility*, **2020**, 32, e13872	4	20
301	Mycophenolate mofetil in refractory inflammatory bowel disease. *Alimentary Pharmacology and Therapeutics*, **2003**, 17, 1365-9	6.1	20
300	Clinical application of dietary therapies in irritable bowel syndrome. *Journal of Gastrointestinal and Liver Diseases*, **2018**, 27, 307-316	1.4	20
299	Efficacy of infliximab in acute severe ulcerative colitis: a single-centre experience. *World Journal of Gastroenterology*, **2013**, 19, 1091-7	5.6	20
298	Anxiety But Not Depression Predicts Poor Outcomes in Inflammatory Bowel Disease. *Inflammatory Bowel Diseases*, **2019**, 25, 1255-1261	4.5	20
297	Beliefs about management of irritable bowel syndrome in primary care: cross-sectional survey in one locality. *Primary Health Care Research and Development*, **2015**, 16, 263-9	1.6	19
296	Rifaximin for the treatment of diarrhea-predominant irritable bowel syndrome. *Expert Review of Gastroenterology and Hepatology*, **2016**, 10, 431-42	4.2	19
295	The natural history of gastro-oesophageal reflux symptoms in the community and its effects on survival: a longitudinal 10-year follow-up study. *Alimentary Pharmacology and Therapeutics*, **2013**, 37, 323-31	6.1	19
294	Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn's disease: A single centre experience. *Journal of Crohnls and Colitis*, **2011**, 5, 324-31	1.5	19
293	Evaluation of a faecal calprotectin care pathway for use in primary care. *Primary Health Care Research and Development*, **2016**, 17, 428-36	1.6	19
292	Long-term efficacy and safety of azathioprine in ulcerative colitis. *Journal of Crohnls and Colitis*, **2015**, 9, 191-7	1.5	18
291	Chemoprevention for gastric cancer. *Baillierels Best Practice and Research in Clinical Gastroenterology*, **2011**, 25, 581-92	2.5	18
290	IBS in 2010: advances in pathophysiology, diagnosis and treatment. *Nature Reviews Gastroenterology and Hepatology*, **2011**, 8, 76-8	24.2	18
289	Systematic review and network meta-analysis: efficacy of drugs for functional dyspepsia. *Alimentary Pharmacology and Therapeutics*, **2021**, 53, 8-21	6.1	18
288	Acupuncture and related therapies for treating irritable bowel syndrome: overview of systematic reviews and network meta-analysis. *Therapeutic Advances in Gastroenterology*, **2019**, 12, 1756284818820438	4.7	17

287	Functional Dyspepsia. *New England Journal of Medicine*, **2016**, 374, 896	59.2	17
286	Pharmacotherapy for Irritable Bowel Syndrome. *Journal of Clinical Medicine*, **2017**, 6,	5.1	17
285	Functional dyspepsia. *Current Opinion in Gastroenterology*, **2015**, 31, 492-8	3	17
284	Irritable Bowel Syndrome: Pathophysiology and Current Therapeutic Approaches. *Handbook of Experimental Pharmacology*, **2017**, 239, 75-113	3.2	17
283	Effectiveness of management strategies for uninvestigated dyspepsia: systematic review and network meta-analysis. *BMJ, The*, **2019**, 367, l6483	5.9	17
282	Systematic Review and Network Meta-Analysis of Medical Therapies to Prevent Recurrence of Post-Operative Crohn's Disease. *Journal of Crohnls and Colitis*, **2019**, 13, 693-701	1.5	17
281	Global prevalence of Barrett's oesophagus and oesophageal cancer in individuals with gastro-oesophageal reflux: a systematic review and meta-analysis. *Gut*, **2021**, 70, 456-463	19.2	17
280	Efficacy and tolerability of methotrexate therapy for refractory Crohn's disease: a large single-centre experience. *Alimentary Pharmacology and Therapeutics*, **2012**, 35, 284-91	6.1	16
279	Dyspepsia. *Current Opinion in Gastroenterology*, **2013**, 29, 662-8	3	16
278	Redundant data in the meta-analysis on Helicobacter pylori eradication. *Annals of Internal Medicine*, **2009**, 151, 513; author reply 513-4	8	16
277	No increase in prevalence of somatization in functional vs organic dyspepsia: a cross-sectional survey. *Neurogastroenterology and Motility*, **2015**, 27, 1024-31	4	15
276	Symptom-based diagnostic criteria for irritable bowel syndrome: the more things change, the more they stay the same. *Gastroenterology Clinics of North America*, **2011**, 40, 87-103	4.4	15
275	Global prevalence of functional constipation according to the Rome criteria: a systematic review and meta-analysis. *The Lancet Gastroenterology and Hepatology*, **2021**, 6, 638-648	18.8	15
274	Irritable Bowel Syndrome-Type Symptoms Are Associated With Psychological Comorbidity, Reduced Quality of Life, and Health Care Use in Patients With Inflammatory Bowel Disease. *Gastroenterology*, **2017**, 153, 324-325	13.3	14
273	Lack of utility of symptoms and signs at first presentation as predictors of inflammatory bowel disease in secondary care. *American Journal of Gastroenterology*, **2015**, 110, 716-24	0.7	14
272	Bathyal demersal fishes of Charlie-Gibbs Fracture Zone region (49–54°N) of the Mid-Atlantic Ridge: II. Baited camera lander observations. *Deep-Sea Research Part II: Topical Studies in Oceanography*, **2013**, 98, 397-406	2.3	14
271	Incidental focal colonic lesions found on (18)Fluorodeoxyglucose positron emission tomography/computed tomography scan: further support for a national guideline on definitive management. *Colorectal Disease*, **2012**, 14, e56-63	2.1	14
270	Comparison of the Rome IV criteria with the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care. *Gut*, **2021**, 70, 1110-1116	19.2	14

269	Infliximab Therapeutic Drug Monitoring Changes Clinical Decisions in a Virtual Biologics Clinic for Inflammatory Bowel Disease. *Inflammatory Bowel Diseases*, **2017**, 23, 2083-2088	4.5	13
268	No Significant Association Between the Fecal Microbiome and the Presence of Irritable Bowel Syndrome-type Symptoms in Patients with Quiescent Inflammatory Bowel Disease. *Inflammatory Bowel Diseases*, **2018**, 24, 1597-1605	4.5	13
267	Validation and modification of a diagnostic scoring system to predict microscopic colitis. *Scandinavian Journal of Gastroenterology*, **2016**, 51, 1206-12	2.4	13
266	Insights into the evaluation and management of dyspepsia: recent developments and new guidelines. *Therapeutic Advances in Gastroenterology*, **2018**, 11, 1756284818805597	4.7	13
265	Recent developments in gastroenterology. *BMJ, The*, **2002**, 325, 1399-402	5.9	12
264	Symptom Stability in Rome IV vs Rome III Irritable Bowel Syndrome. *American Journal of Gastroenterology*, **2021**, 116, 362-371	0.7	12
263	Systematic review with meta-analysis: global prevalence of uninvestigated dyspepsia according to the Rome criteria. *Alimentary Pharmacology and Therapeutics*, **2020**, 52, 762-773	6.1	12
262	Efficacy of surgical or endoscopic treatment of idiopathic achalasia: a systematic review and network meta-analysis. *The Lancet Gastroenterology and Hepatology*, **2021**, 6, 30-38	18.8	12
261	Efficacy of a low FODMAP diet in irritable bowel syndrome: systematic review and network meta-analysis. *Gut*, **2021**,	19.2	12
260	Cyclic vomiting syndrome: a case series and review of the literature. *Frontline Gastroenterology*, **2018**, 9, 2-9	2.6	11
259	Costs of adalimumab versus infliximab as first-line biological therapy for luminal Crohn's disease. *Journal of Crohnls and Colitis*, **2014**, 8, 375-83	1.5	11
258	Dyspepsia. *BMJ, The*, **2013**, 347, f5059	5.9	11
257	Laxatives for chronic constipation in adults. *BMJ, The*, **2012**, 345, e6168	5.9	11
256	A Novel Method to Classify and Subgroup Patients With IBS Based on Gastrointestinal Symptoms and Psychological Profiles. *American Journal of Gastroenterology*, **2021**, 116, 372-381	0.7	11
255	Factors affecting clinical decision-making in inflammatory bowel disease and the role of point-of-care calprotectin. *Therapeutic Advances in Gastroenterology*, **2018**, 11, 1756283X17744739	4.7	10
254	Fatigue in Inflammatory Bowel Disease Reflects Mood and Symptom-Reporting Behavior Rather Than Biochemical Activity or Anemia. *Clinical Gastroenterology and Hepatology*, **2018**, 16, 1165-1167	6.9	10
253	Initial management of dyspepsia in primary care: an evidence-based approach. *British Journal of General Practice*, **2013**, 63, 498-9	1.6	10
252	The Effect of Antidepressants on the Course of Inflammatory Bowel Disease. *Canadian Journal of Gastroenterology and Hepatology*, **2018**, 2018, 2047242	2.8	10

251	Prevalence of, and predictors of, bile acid diarrhea in outpatients with chronic diarrhea: A follow-up study. *Neurogastroenterology and Motility*, **2019**, 31, e13666	4	9
250	Poor predictive value of lower gastrointestinal alarm features in the diagnosis of colorectal cancer in 1981 patients in secondary care. *Alimentary Pharmacology and Therapeutics*, **2017**, 45, 91-99	6.1	9
249	Eradicating Helicobacter pylori in functional dyspepsia. *Gastroenterology*, **2012**, 142, 1613-4	13.3	9
248	Quality of Care and the Irritable Bowel Syndrome: Is Now the Time to Set Standards?. *American Journal of Gastroenterology*, **2018**, 113, 167-169	0.7	9
247	The Importance of Smoking Cessation in Improving Disease Course in Crohn's Disease. *American Journal of Gastroenterology*, **2016**, 111, 1198	0.7	8
246	Whom should we "test and treat" for Helicobacter pylori?. *BMJ, The*, **2014**, 348, g3320	5.9	8
245	Managing dyspepsia. *Current Gastroenterology Reports*, **2009**, 11, 288-94	5	8
244	Development of a real-time patient-reported outcome measure for symptom assessment in patients with functional dyspepsia using the experience sampling method. *Neurogastroenterology and Motility*, **2019**, 31, e13496	4	8
243	Rational investigations in irritable bowel syndrome. *Frontline Gastroenterology*, **2020**, 11, 140-147	2.6	8
242	Derivation and validation of a diagnostic test for irritable bowel syndrome using latent class analysis. *Alimentary Pharmacology and Therapeutics*, **2017**, 45, 824-832	6.1	7
241	Randomized controlled trial: a pilot study of a psychoeducational intervention for fatigue in patients with quiescent inflammatory bowel disease. *Therapeutic Advances in Chronic Disease*, **2019**, 10, 2040622319838439	4.9	7
240	High prevalence of irritable bowel syndrome-type symptoms in microscopic colitis: implications for treatment. *Therapeutic Advances in Gastroenterology*, **2018**, 11, 1756284818783600	4.7	7
239	Linaclotide: new mechanisms and new promise for treatment in constipation and irritable bowel syndrome. *Therapeutic Advances in Chronic Disease*, **2013**, 4, 268-76	4.9	7
238	Clinical trial: knowledge of negative Helicobacter pylori status reduces subsequent dyspepsia-related resource use. *Alimentary Pharmacology and Therapeutics*, **2007**, 26, 1267-75	6.1	7
237	Irritable bowel syndrome. *Clinical Evidence*, **2012**, 2012,		7
236	Review: Prevention and management of gastric cancer. *Helicobacter*, **2020**, 25 Suppl 1, e12740	4.9	7
235	Impact of Psychological Comorbidity on the Prognosis of Irritable Bowel Syndrome. *American Journal of Gastroenterology*, **2021**, 116, 1485-1494	0.7	7
234	Common mental disorders in irritable bowel syndrome: pathophysiology, management, and considerations for future randomised controlled trials. *The Lancet Gastroenterology and Hepatology* , **2021**, 6, 401-410	18.8	7

233	Efficacy of Oral, Topical, or Combined Oral and Topical 5-Aminosalicylates, in Ulcerative Colitis: Systematic Review and Network Meta-analysis. *Journal of Crohnls and Colitis*, **2021**, 15, 1184-1196	1.5	7
232	Postoperative prophylaxis in Crohn's disease after intestinal resection: a retrospective analysis. *Frontline Gastroenterology*, **2017**, 8, 203-209	2.6	6
231	Treatment of irritable bowel syndrome with diarrhoea using titrated ondansetron (TRITON): study protocol for a randomised controlled trial. *Trials*, **2019**, 20, 517	2.8	6
230	Screening for bile acid diarrhoea in suspected irritable bowel syndrome. *Gut*, **2015**, 64, 851	19.2	6
229	Ongoing Symptoms in Ulcerative Colitis Patients in Remission: Irritable Bowel Syndrome or Gastrointestinal Symptoms in the Absence of Inflammation?. *Inflammatory Bowel Diseases*, **2017**, 23, E4-E5	4.5	6
228	Use of Biomarkers in Irritable Bowel Syndrome: To Predict the Future, Look at the Past. *Clinical and Translational Gastroenterology*, **2015**, 6, e116	4.2	6
227	The American College of Gastroenterology irritable bowel syndrome monograph: translating systematic review data to clinical practice. *Gastroenterology*, **2010**, 138, 789-91; author reply 791-2	13.3	6
226	Efficacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized, controlled trials. *Diseases of the Colon and Rectum*, **2009**, 52, 1805; author reply 1806	3.1	6
225	The possible risks of proton pump inhibitors. *Medical Journal of Australia*, **2016**, 205, 292-3	4	6
224	Fatigue and its associated factors in microscopic colitis. *Therapeutic Advances in Gastroenterology*, **2018**, 11, 1756284818799599	4.7	6
223	A Review of the Evidence and Recommendations on Communication Skills and the Patient-Provider Relationship: A Rome Foundation Working Team Report. *Gastroenterology*, **2021**, 161, 1670-1688.e7	13.3	6
222	Peppermint Oil in Irritable Bowel Syndrome. *Gastroenterology*, **2020**, 159, 395-396	13.3	5
221	General practitioners' perceptions of irritable bowel syndrome: a Q-methodological study. *Family Practice*, **2018**, 35, 74-79	1.9	5
220	Stool as a treatment for IBS: more questions than answers?. *The Lancet Gastroenterology and Hepatology*, **2018**, 3, 2-3	18.8	5
219	Functional bowel symptoms in quiescent inflammatory bowel disease: more than just irritable bowel syndrome?. *Gastroenterology*, **2014**, 147, 1176-7	13.3	5
218	Masquerading gastrointestinal polyps: air on the side of caution? Cystic pneumatosis. *Gastroenterology*, **2014**, 146, e9-10	13.3	5
217	Reducing the need for random colonic biopsies in patients with diarrhea. *American Journal of Gastroenterology*, **2015**, 110, 351-2	0.7	5
216	Probiotics in irritable bowel syndrome: underachievers or underpowered?. *Alimentary Pharmacology and Therapeutics*, **2010**, 31, 922-3; author reply 923-4	6.1	5

215	Overlap of Rome IV Irritable Bowel Syndrome and Functional Dyspepsia and Effect on Natural History: A Longitudinal Follow-Up Study. *Clinical Gastroenterology and Hepatology*, **2021**,	6.9	5
214	Natural History and Disease Impact of Rome IV Vs Rome III Irritable Bowel Syndrome: A Longitudinal Follow-Up Study. *Clinical Gastroenterology and Hepatology*, **2021**,	6.9	5
213	Best management of irritable bowel syndrome. *Frontline Gastroenterology*, **2021**, 12, 303-315	2.6	5
212	Evidence-based management of ulcerative colitis. *Minerva Gastroenterologica E Dietologica*, **2012**, 58, 87-99	1.6	5
211	Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis.. *Gut*, **2021**,	19.2	5
210	Letter: causes of fatigue in inflammatory bowel disease remain uncertain. *Alimentary Pharmacology and Therapeutics*, **2017**, 45, 762-763	6.1	4
209	A Bidirectional Relationship Between Symptom Reporting and Perceived Stress, But Not Disease Activity, in Inflammatory Bowel Disease: More Questions Than Answers?. *Gastroenterology*, **2017**, 153, 1444-1445	13.3	4
208	Cyclic Vomiting Syndrome: Randomized Controlled Trials Are also Needed in Adults. *American Journal of Gastroenterology*, **2017**, 112, 1752-1753	0.7	4
207	Symbiotics in irritable bowel syndrome--better than probiotics alone?. *Current Opinion in Clinical Nutrition and Metabolic Care*, **2015**, 18, 485-9	3.8	4
206	Acupuncture for irritable bowel syndrome. *Gastroenterology*, **2012**, 143, 1683-4	13.3	4
205	Efficacy of traditional chinese medicine in functional constipation. *American Journal of Gastroenterology*, **2011**, 106, 1003; author reply 1003-4	0.7	4
204	VSL#3 and remission in active ulcerative colitis: larger studies required. *American Journal of Gastroenterology*, **2011**, 106, 547; author reply 547-8	0.7	4
203	10-biomarker algorithm to identify irritable bowel syndrome. *Alimentary Pharmacology and Therapeutics*, **2009**, 30, 95-6; author reply 96-7	6.1	4
202	Utility of fecal calprotectin in differentiating active inflammatory bowel disease from coexistent irritable bowel syndrome. *American Journal of Gastroenterology*, **2011**, 106, 166; author reply 166-7	0.7	4
201	Direction of the brain--gut pathway in functional gastrointestinal disorders. *Gut*, **2012**, 61, 1368	19.2	4
200	Efficacy of eradication therapy for functional dyspepsia: updated systematic review and meta-analysis.. *Gut*, **2022**,	19.2	4
199	Longitudinal follow-up of a novel classification system for irritable bowel syndrome: natural history and prognostic value. *Alimentary Pharmacology and Therapeutics*, **2021**, 53, 1126-1137	6.1	4
198	Does Helicobacter pylori really cause duodenal ulcers? Yes. *BMJ, The*, **2009**, 339, b2784	5.9	4

197	The Efficacy of Probiotics in the Therapy of Irritable Bowel Syndrome (IBS). *American Journal of Gastroenterology*, **2008**, 103, S481	0.7	4
196	Constipation Predominant Irritable Bowel Syndrome and Functional Constipation Are Not Discrete Disorders: A Machine Learning Approach. *American Journal of Gastroenterology*, **2021**, 116, 142-151	0.7	4
195	Bidirectional brain-gut axis effects influence mood and prognosis in IBD: a systematic review and meta-analysis. *Gut*, **2021**,	19.2	4
194	Commentary: estimating the prevalence of IBS globally-past, present and future. *Alimentary Pharmacology and Therapeutics*, **2020**, 51, 198-199	6.1	4
193	Psychometric evaluation of an experience sampling method-based patient-reported outcome measure in functional dyspepsia. *Neurogastroenterology and Motility*, **2021**, 33, e14136	4	4
192	Systematic review and network meta-analysis: efficacy of licensed drugs for abdominal bloating in irritable bowel syndrome with constipation. *Alimentary Pharmacology and Therapeutics*, **2021**, 54, 98-108	6.1	4
191	Ciclosporin or Infliximab as Rescue Therapy in Acute Glucorticosteroid-Refractory Ulcerative Colitis: Systematic Review and Network Meta-Analysis. *Journal of Crohnls and Colitis*, **2021**, 15, 733-741	1.5	4
190	Management of irritable bowel syndrome. *Minerva Gastroenterologica E Dietologica*, **2009**, 55, 273-87	1.6	4
189	Minimal differences in prevalence and spectrum of organic disease at upper gastrointestinal endoscopy between selected secondary care patients with symptoms of gastro-oesophageal reflux or dyspepsia. *Scandinavian Journal of Gastroenterology*, **2017**, 52, 396-402	2.4	3
188	Use of Probiotics in Hospitalized Adults to Prevent Clostridium difficile Infection: DownGRADE the Quality of Evidence?. *Gastroenterology*, **2017**, 153, 1451-1452	13.3	3
187	Possible Redundant Data in the Network Meta-analysis of Pharmacological Therapies for Opioid-Induced Constipation. *Journal of Pain and Symptom Management*, **2018**, 55, e8-e9	4.8	3
186	Poor Correlation Between Patient-reported and Endoscopic Components of the Mayo Score in Ulcerative Colitis. *Gastroenterology*, **2016**, 150, 1037-9	13.3	3
185	Multiple myeloma presenting in association with gastric phytobezoar. *Clinical Case Reports (discontinued)*, **2017**, 5, 1493-1495	0.7	3
184	Do Lay People Accept a Positive Diagnosis of Irritable Bowel Syndrome?. *Gastroenterology*, **2015**, 149, 252-3	13.3	3
183	ROME III Criteria for Functional Gastrointestinal Disorders: Too Much Overlap to Be Useful?. *Gastroenterology*, **2011**, 140, S-725-S-726	13.3	3
182	Applicability of the reported prevalence of bile salt malabsorption in irritable bowel. *Alimentary Pharmacology and Therapeutics*, **2010**, 31, 161-2; author reply 162-4	6.1	3
181	Alverine citrate, simeticone, and Rome III irritable bowel syndrome. *Alimentary Pharmacology and Therapeutics*, **2010**, 31, 767-8; author reply 768-9	6.1	3
180	Infliximab rescue therapy in ulcerative colitis, and the effect on subsequent colectomy rates. *Alimentary Pharmacology and Therapeutics*, **2010**, 32, 1294-5	6.1	3

179	Effect of oral zinc in hepatic encephalopathy remains unclear. *Alimentary Pharmacology and Therapeutics*, **2010**, 32, 1405-6; author reply 1406-7	6.1	3
178	Overlap among the functional gastrointestinal disorders. *American Journal of Gastroenterology*, **2010**, 105, 2512	0.7	3
177	In irritable bowel syndrome, antispasmodics and antidepressants improve abdominal pain and global assessment and symptom scores, but there is no evidence for the effectiveness of bulking agents. *Evidence-Based Medicine*, **2012**, 17, 114-5		3
176	Is the benefit of granulocyte monocyte adsorptive apheresis in ulcerative colitis overstated?. *Digestive Diseases and Sciences*, **2010**, 55, 1803; author reply 1803-4	4	3
175	Functional gastrointestinal disorders in inflammatory bowel disease: Time for a paradigm shift?. *World Journal of Gastroenterology*, **2020**, 26, 3712-3719	5.6	3
174	Longitudinal follow-up study: effect of psychological co-morbidity on the prognosis of inflammatory bowel disease. *Alimentary Pharmacology and Therapeutics*, **2021**, 54, 441-450	6.1	3
173	Imipramine for Treatment of Esophageal Hypersensitivity and Functional Heartburn. *American Journal of Gastroenterology*, **2016**, 111, 1358	0.7	3
172	Efficacy of glutamine in postinfection IBS. *Gut*, **2019**, 68, 1905-1906	19.2	3
171	Effect of ACE inhibitors and angiotensin II receptor blockers on disease outcomes in inflammatory bowel disease. *Gut*, **2021**, 70, 218-219	19.2	3
170	Chronic constipation in adults: Contemporary perspectives and clinical challenges. 1: Epidemiology, diagnosis, clinical associations, pathophysiology and investigation. *Neurogastroenterology and Motility*, **2021**, 33, e14050	4	3
169	The Glasgow Prognostic Score at the Time of Palliative Esophageal Stent Insertion is a Predictive Factor of 30-Day Mortality and Overall Survival. *Journal of Clinical Gastroenterology*, **2018**, 52, 223-228	3	3
168	AGA Clinical Practice Update on Management of Chronic Gastrointestinal Pain in Disorders of Gut-Brain Interaction: Expert Review. *Clinical Gastroenterology and Hepatology*, **2021**, 19, 2481-2488.e1	6.9	3
167	Systematic review with meta-analysis: risk factors for Barrett's oesophagus in individuals with gastro-oesophageal reflux symptoms. *Alimentary Pharmacology and Therapeutics*, **2021**, 53, 968-976	6.1	3
166	Depression, Antidepressants, and Inflammatory Bowel Disease: Implications for Future Models of Care. *Gastroenterology*, **2019**, 156, 2345-2347	13.3	2
165	Efficacy of Eluxadoline in Irritable Bowel Syndrome With Diarrhea. *American Journal of Gastroenterology*, **2020**, 115, 483-484	0.7	2
164	PTU-075 Systematic Review And Meta-analysis: Sensitivity And Specificity Of Tc-99m Hmpao Labelled White Cell Scintigraphy In The Diagnosis Of Active Inflammatory Bowel Disease. *Gut*, **2014**, 63, A71.2-A71	19.2	2
163	Death knell for placebo-controlled trials in chronic idiopathic constipation?. *Gastroenterology*, **2013**, 145, 897-8	13.3	2
162	First-line eradication therapy for Helicobacter pylori: time for a change?. *Gastroenterology*, **2013**, 144, 652-3	13.3	2

161	Reply to Machicado JD, Villafuerte-Galvez J, Marcos LA, Prevalence of irritable bowel syndrome in South America. *Clinical Gastroenterology and Hepatology*, **2013**, 11, 102-3	6.9	2
160	Balancing risks and benefits of prucalopride for the treatment of chronic constipation in Asians. *Neurogastroenterology and Motility*, **2013**, 25, 89	4	2
159	Making a positive diagnosis of irritable bowel syndrome. *British Journal of General Practice*, **2017**, 67, 580-581	1.6	2
158	Irritable bowel syndrome and somatization. *Neurogastroenterology and Motility*, **2015**, 27, 740	4	2
157	Aetiopathogenesis of functional dyspepsia. *Gut*, **2015**, 64, 1182-3	19.2	2
156	Letter: bile acid diarrhoea is not a rare cause of diarrhoea in secondary care. *Alimentary Pharmacology and Therapeutics*, **2014**, 40, 216	6.1	2
155	Efficacy of granulocyte/monocyte apheresis for moderate to severe Crohn's disease. *Gut*, **2013**, 62, 653	19.2	2
154	Efficacy of antidepressants in irritable bowel syndrome: an updated systematic review and meta-analysis controlling for depression. *Gut*, **2011**, 60, A154-A155	19.2	2
153	Defining a responder in treatment trials for chronic idiopathic constipation. *Alimentary Pharmacology and Therapeutics*, **2011**, 33, 285-6; author reply 286-7	6.1	2
152	Is otilonium bromide globally effective in irritable bowel syndrome?. *Alimentary Pharmacology and Therapeutics*, **2011**, 34, 1034-5; author reply 1035-6	6.1	2
151	Renzapride in IBS: is efficacy in the eye of the beholder?. *Alimentary Pharmacology and Therapeutics* , **2010**, 32, 113-4; author reply 114-5	6.1	2
150	Dyspepsia and irritable bowel syndrome: mutually exclusive conditions?. *Alimentary Pharmacology and Therapeutics*, **2010**, 32, 612-3; author reply 613	6.1	2
149	Efficacy of azathioprine versus mesalazine in postoperative Crohn's disease. *Gut*, **2010**, 59, 1731-2	19.2	2
148	"Power" of selective serotonin reuptake inhibitors in irritable bowel syndrome. *Clinical Gastroenterology and Hepatology*, **2010**, 8, 313-4; author reply 314	6.9	2
147	Treatment of chronic gastro-oesophageal reflux disease. *BMJ, The*, **2009**, 339, b2481	5.9	2
146	Generalized anxiety disorder and irritable bowel syndrome. *Alimentary Pharmacology and Therapeutics*, **2009**, 30, 1087-8; author reply 1088-9	6.1	2
145	Biochemical Tests for Bile Acid Diarrhea: Real-World Studies Required. *American Journal of Gastroenterology*, **2021**, 116, 833-834	0.7	2
144	Helicobacter pylori infection. *Clinical Evidence*, **2009**, 2009,		2

143	Irritable bowel syndrome: dietary interventions. *Clinical Evidence*, **2015**, 2015,		2
142	Association of proton-pump inhibitor use with adverse health outcomes: A systematic umbrella review of meta-analyses of cohort studies and randomised controlled trials. *British Journal of Clinical Pharmacology*, **2021**,	3.8	2
141	Letter: faecal microbiota transplantation for irritable bowel syndrome-room for improvement. *Alimentary Pharmacology and Therapeutics*, **2020**, 52, 923-924	6.1	2
140	Chronic constipation in adults: Contemporary perspectives and clinical challenges. 2: Conservative, behavioural, medical and surgical treatment. *Neurogastroenterology and Motility*, **2021**, 33, e14070	4	2
139	Prevalence of Primary Sclerosing Cholangitis in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. *Gastroenterology*, **2021**, 161, 1865-1877	13.3	2
138	The impact of the coronavirus (COVID-19) pandemic on individuals with gastrointestinal disorders: A protocol of an international collaborative study. *Journal of Psychosomatic Research*, **2021**, 148, 110561	4.1	2
137	Definitions and Classifications of Irritable Bowel Syndrome1-21		2
136	Should we step-up or step-down in the treatment of new-onset dyspepsia in primary care? **2009**, 119, 391-6		2
135	Efficacy of mesalazine in IBS. *Gut*, **2016**, 65, 187-8	19.2	1
134	Reactive Versus Proactive Therapeutic Drug Monitoring in Inflammatory Bowel Disease Patients Treated With Infliximab: A Self-Fulfilling Prophecy. *Clinical Gastroenterology and Hepatology*, **2017**, 15, 1638	6.9	1
133	Mizagliflozin for the Treatment of Functional Constipation: Are New Drugs Better?. *Gastroenterology*, **2019**, 156, 818-820	13.3	1
132	Functional Gastrointestinal Symptoms in Inflammatory Bowel Disease: Rising to the Challenge. *Clinical Gastroenterology and Hepatology*, **2019**, 17, 572-573	6.9	1
131	Letter: meta-analysis of prebiotics, probiotics, synbiotics and antibiotics in IBS. Authors' reply. *Alimentary Pharmacology and Therapeutics*, **2019**, 49, 1254-1255	6.1	1
130	Lubiprostone Is Effective in Treating Functional Bowel Disease With Constipation. *Clinical Gastroenterology and Hepatology*, **2015**, 13, 1378-9	6.9	1
129	Ondansetron and irritable bowel syndrome. *Gut*, **2015**, 64, 1181	19.2	1
128	VSL#3 in Postoperative Crohn's Disease. *Clinical Gastroenterology and Hepatology*, **2015**, 13, 1855	6.9	1
127	Central pain processing in irritable bowel syndrome is modulated by mood: a mechanism for the beneficial effects of antidepressants?. *Gastroenterology*, **2015**, 148, 247-8	13.3	1
126	Faecal incontinence is not rare in irritable bowel syndrome. *Frontline Gastroenterology*, **2020**, 11, 494-496	4.6	1

125	Use of Lactulose Breath Tests to Predict Response to Rifaximin in Irritable Bowel Syndrome With Diarrhea: The Positives and Negatives. *American Journal of Gastroenterology*, **2020**, 115, 955-956	0.7	1
124	Polyethylene glycol-based laxatives for chronic constipation - Authors' reply. *The Lancet Gastroenterology and Hepatology*, **2020**, 5, 110-111	18.8	1
123	Simple Clinical Colitis Activity Index: Accurate Assessment of Inflammatory Burden or Reflection of Low Mood and Somatoform Behavior?. *American Journal of Gastroenterology*, **2016**, 111, 900-1	0.7	1
122	Psychological Comorbidity and Inflammatory Bowel Disease Activity: Cause or Effect?. *Clinical Gastroenterology and Hepatology*, **2016**, 14, 1061-2	6.9	1
121	Utility of the Oral Capsaicin Test in Diagnosing Functional Dyspepsia. *American Journal of Gastroenterology*, **2018**, 113, 1257-1258	0.7	1
120	Assessing the efficacy of peripherally acting μ-opioid receptor antagonists (PAMORAs) in the treatment of opioid-induced constipation: authors reply. *Gut*, **2019**, 68, 1530-1531	19.2	1
119	Polyethylene glycol in constipation-predominant irritable bowel syndrome. *American Journal of Gastroenterology*, **2014**, 109, 135	0.7	1
118	The fall and rise of 5-hydroxytryptamine receptor antagonists in irritable bowel syndrome with diarrhea. *Gastroenterology*, **2014**, 147, 527-8	13.3	1
117	Diagnosing irritable bowel syndrome with a combination of biomarkers and "psychomarkers". *Gastroenterology*, **2014**, 146, 1418-20	13.3	1
116	Letter: the effects of overlapping symptoms on the response to PPI therapy in GERD. *Alimentary Pharmacology and Therapeutics*, **2012**, 36, 207; author 207-8	6.1	1
115	Combining biomarkers in irritable bowel syndrome: a forward step toward making a positive diagnosis and directing therapy?. *Gastroenterology*, **2015**, 148, 1471-3	13.3	1
114	Rates of upper gastrointestinal endoscopy and gastro-oesophageal malignancy outcomes. *Gut*, **2014**, 63, 703	19.2	1
113	Medical or surgical therapy for gastroesophageal reflux disease?. *Gastroenterology*, **2011**, 141, 1938-9	13.3	1
112	Do dried plums really help constipation?. *Alimentary Pharmacology and Therapeutics*, **2011**, 33, 1258-9; author reply 1259	6.1	1
111	Reporting of relapse rates in a trial of mesalazine for ulcerative colitis. *Alimentary Pharmacology and Therapeutics*, **2010**, 32, 1205-6; author reply 1206-7	6.1	1
110	Testing for Celiac Disease in Patients With Symptoms of Irritable Bowel Syndrome Reply. *JAMA - Journal of the American Medical Association*, **2009**, 301, 1126	27.4	1
109	Image of the month. Autoimmune pancreatitis. *Gastroenterology*, **2005**, 129, 785, 1141	13.3	1
108	Hemobiliary from arterial pseudoaneurysm. *Gastroenterology*, **2002**, 122, 1720, 2098	13.3	1

107	A specific microbiota signature is associated to various degrees of ulcerative colitis as assessed by a machine learning approach.. *Gut Microbes*, **2022**, 14, 2028366	8.8	1
106	Efficacy of Ondansetron for Irritable Bowel Syndrome With Diarrhea. *American Journal of Gastroenterology*, **2021**, 116, 428-429	0.7	1
105	Irritable bowel syndrome. *Clinical Evidence*, **2010**, 2010,		1
104	Helicobacter pylori eradication: gastric cancer prevention. *Clinical Evidence*, **2015**, 2015,		1
103	Irritable bowel syndrome: a spotlight on future research needs. *The Lancet Gastroenterology and Hepatology*, **2021**, 6, 419-422	18.8	1
102	Screening for Celiac Disease in Individuals With Symptoms Suggestive of Irritable Bowel Syndrome: Still a Worthwhile Exercise. *Gastroenterology*, **2016**, 151, 368-70	13.3	1
101	PTU-127 Efficacy of Linaclotide in Constipation-Predominant Irritable Bowel Syndrome in Routine Clinical Practice: A Multicentre Experience. *Gut*, **2016**, 65, A119-A119	19.2	1
100	Depression Is Associated With Subjective Measures of Crohn's Disease Activity During Longitudinal Follow-up. *Gastroenterology*, **2016**, 151, 762-3	13.3	1
99	Relative Efficacy of Naloxegol and Polyethylene Glycol 3350 in Opioid-Induced Constipation. *American Journal of Gastroenterology*, **2019**, 114, 1694	0.7	1
98	Probiotics for Treating Irritable Bowel Syndrome: Are Bugs the Best Drugs?. *Gastroenterology*, **2018**, 155, 2019-2021	13.3	1
97	Reply. *Clinical Gastroenterology and Hepatology*, **2021**, 19, 1737-1738	6.9	1
96	Derivation and validation of a novel method to subgroup patients with functional dyspepsia: beyond upper gastrointestinal symptoms. *Alimentary Pharmacology and Therapeutics*, **2021**, 53, 253-264	6.1	1
95	Effect of gastro-esophageal reflux symptoms on the risk of Barrett's esophagus: A systematic review and meta-analysis. *Journal of Gastroenterology and Hepatology (Australia)*,	4	1
94	Defining the relationship between clinical and biochemical disease activity indices and perceived stress in inflammatory bowel disease. *Gastroenterology*, **2015**, 149, 1632-4	13.3	0
93	Predicting Response to Rifaximin in Irritable Bowel Syndrome with Diarrhea: Is the Answer Blowing in the Wind?. *Gastroenterology*, **2020**, 158, 1508-1510	13.3	0
92	Histologic Criteria to Define Irritable Bowel Syndrome: Within the Realms of Possibility?. *Gastroenterology*, **2018**, 154, 1539-1541	13.3	0
91	Letter: is there a bi-directional relationship between depression and IBD?. *Alimentary Pharmacology and Therapeutics*, **2014**, 40, 213	6.1	0
90	Prognosis of patients with Rome IV-defined versus physician-diagnosed irritable bowel syndrome: Longitudinal follow-up study. *Neurogastroenterology and Motility*, **2021**, e14282	4	0

89	Adverse events in trials of licensed drugs for irritable bowel syndrome with constipation or diarrhea: Systematic review and meta-analysis. *Neurogastroenterology and Motility*, **2021**, e14279	4	0
88	Healthy Mind, Healthy Body: Chronic Depression May Predate the Development of Inflammatory Bowel Disease by up to 9 Years. *Gastroenterology*, **2021**, 160, 2611-2613	13.3	0
87	Sarcopenia, severe anxiety and increased C-reactive protein are associated with severe fatigue in patients with inflammatory bowel diseases. *Scientific Reports*, **2021**, 11, 15251	4.9	0
86	Intending to Treat Patients With Irritable Bowel Syndrome With Cognitive-Behavioral Therapy. *Gastroenterology*, **2018**, 155, 2024	13.3	0
85	Systematic review with meta-analysis: association of Helicobacter pylori infection with gastro-oesophageal reflux and its complications. *Alimentary Pharmacology and Therapeutics*, **2021**, 54, 988-998	6.1	0
84	Prevalence and impact of Rome IV versus Rome III irritable bowel syndrome in patients with inflammatory bowel disease. *Neurogastroenterology and Motility*, **2021**, e14256	4	0
83	Characteristics of, and natural history among, individuals with Rome IV functional bowel disorders. *Neurogastroenterology and Motility*, **2021**, e14268	4	0
82	Latent class analysis does not support the existence of Rome IV functional bowel disorders as discrete entities.. *Neurogastroenterology and Motility*, **2022**, e14391	4	0
81	Reply. *Clinical Gastroenterology and Hepatology*, **2017**, 15, 1315-1316	6.9	
80	Letter: NICE referral criteria for lower gastrointestinal alarm features - not ideal but not poor either. Authors' reply. *Alimentary Pharmacology and Therapeutics*, **2017**, 45, 1176	6.1	
79	Response to Letter by Moulton et al. *Inflammatory Bowel Diseases*, **2019**, 25, e99	4.5	
78	Pinaverium in Irritable Bowel Syndrome: Old Drug, New Tricks?. *Clinical Gastroenterology and Hepatology*, **2015**, 13, 1548-9	6.9	
77	Comment on "A randomized clinical trial of Saccharomyces cerevisiae versus placebo in the irritable bowel syndrome" by Guillaume Pineton de Chambrun et al. [Digestive and Liver Disease 2015;47:119-24]. *Digestive and Liver Disease*, **2015**, 47, 437	3.3	
76	Irritable Bowel Syndrome and Colorectal Neoplasia: "Cause and Effect" or Chance Association?. *Gastroenterology*, **2015**, 149, 502-3	13.3	
75	Efficacy of hypnotherapy in one thousand patients with irritable bowel syndrome. *Alimentary Pharmacology and Therapeutics*, **2015**, 41, 1222-3	6.1	
74	Practical plus personal: a refreshing approach to careers advice by the British Society of Gastroenterology Taster Course. *Frontline Gastroenterology*, **2020**, 11, 494	2.6	
73	Defining the relationship between depression and disease activity in IBD using clinical disease activity indices: merit or misnomer?. *American Journal of Gastroenterology*, **2018**, 113, 773-774	0.7	
72	Proton pump inhibitors and oesophageal cancer: Flawed methodology and false alarms. *Cancer Epidemiology*, **2018**, 54, 137-138	2.8	

71	Defining the functional gastrointestinal disorders is challenging: are clinical symptoms alone sufficient?. *Scandinavian Journal of Gastroenterology*, **2018**, 53, 140	2.4
70	Efficacy of linaclotide in irritable bowel syndrome with constipation: Real-world data. *Neurogastroenterology and Motility*, **2018**, 30, e13328	4
69	Derivation and Validation of a Panel of Exhaled Volatile Organic Compounds in Differentiating Irritable Bowel Syndrome From Health. *Gastroenterology*, **2016**, 151, 1245-1246	13.3
68	Response to Levenstein and Prantera. *American Journal of Gastroenterology*, **2016**, 111, 1499	0.7
67	PTU-128 Prevalence and Management of Irritable Bowel Syndrome Seen in Colorectal Surgery and Gastroenterology Clinics. *Gut*, **2016**, 65, A120.1-A120	19.2
66	PTU-137 Enhanced Diagnostic Performance of Symptom-Based Criteria for Irritable Bowel Syndrome by History and Diagnostic Evaluation. *Gut*, **2016**, 65, A125.1-A125	19.2
65	Letter: deleterious effects of smoking on post-operative Crohn's disease - authors' reply. *Alimentary Pharmacology and Therapeutics*, **2016**, 43, 1248	6.1
64	PTU-117 Screening for Coeliac Disease in Irritable Bowel Syndrome Is Still Worthwhile: An Updated Systematic Review and Meta-Analysis. *Gut*, **2016**, 65, A113.2-A113	19.2
63	Antibiotic use and subsequent development of functional gastrointestinal disorders: effect of symptom-reporting and consultation behavior. *Neurogastroenterology and Motility*, **2016**, 28, 449-50	4
62	PWE-098 Earlier Use Of Azathioprine In Ulcerative Colitis Does Not Alter Subsequent Need For Hospitalisation, Biologic Therapy, Or Colectomy. *Gut*, **2014**, 63, A167.1-A167	19.2
61	PWE-185 Beliefs About Management Of Irritable Bowel Syndrome In Primary Care: Cross-sectional Survey. *Gut*, **2014**, 63, A207.1-A207	19.2
60	PTH-106 Bile Acid Diarrhoea Masquerades As Diarrhoea-predominant Irritable Bowel Syndrome: Results From A Dual Centre Prospective Study. *Gut*, **2014**, 63, A257.2-A258	19.2
59	A patient with chronic diarrhea of unknown cause. *Clinical Gastroenterology and Hepatology*, **2013**, 11, e27-8	6.9
58	Letter: irritable bowel syndrome is significantly associated with somatisation - authors' reply. *Alimentary Pharmacology and Therapeutics*, **2015**, 41, 791-2	6.1
57	Letter: therapeutic trial is more informative than SeHCAT to diagnose bile acid malabsorption--authors' reply. *Alimentary Pharmacology and Therapeutics*, **2015**, 42, 781	6.1
56	PTU-068 Outcomes of disease modifying therapy delivered to crohn disease patients following intestinal resection. *Gut*, **2015**, 64, A90.1-A90	19.2
55	PTU-067 How are postoperative crohn patients followed up? a retrospective analysis from a tertiary referral centre. *Gut*, **2015**, 64, A89.2-A89	19.2
54	PTU-066 Characteristics and outcomes of patients undergoing second intestinal resection for crohn disease in a tertiary referral centre. *Gut*, **2015**, 64, A89.1-A89	19.2

53	PTU-089 Are clinical indices of inflammatory bowel disease activity superior to patient opinion at predicting activity as defined by faecal calprotectin?. *Gut*, **2015**, 64, A100.1-A100	19.2
52	PTU-090 Prevalence and impact of irritable bowel type-symptoms in quiescent inflammatory bowel disease. *Gut*, **2015**, 64, A100.2-A100	19.2
51	PTU-065 The influence of smoking on need for surgery and post-operative outcomes in crohn disease. *Gut*, **2015**, 64, A88.2-A89	19.2
50	PTU-176 Systematic review with meta-analysis: prevalence of bile acid malabsorption in irritable bowel syndrome with diarrhoea. *Gut*, **2015**, 64, A140.2-A141	19.2
49	PTU-086 Outcomes of all surgery for ulcerative colitis over a 12-month period at a tertiary referral ibd unit. *Gut*, **2015**, 64, A98.2-A99	19.2
48	Epidemiology of Dyspepsia **2014**, 158-171	
47	How to Read a Systematic Review and Meta-Analysis **2014**, 48-57	
46	Letter: effects of iron therapy after non-variceal acute upper gastrointestinal bleeding. *Alimentary Pharmacology and Therapeutics*, **2014**, 39, 346	6.1
45	PWE-177 A Systematic Review Of Antidepressants In Irritable Bowel Syndrome: A Qualitative Analysis. *Gut*, **2014**, 63, A203.1-A203	19.2
44	Treatment of Helicobacter pylori in Latin America. *Lancet, The*, **2012**, 379, 407; author reply 408-9	40
43	Hypertransaminasaemia and coeliac disease: authors reply. *Alimentary Pharmacology and Therapeutics*, **2012**, 35, 203-204	6.1
42	Response to Neis et al. *American Journal of Gastroenterology*, **2013**, 108, 1930	0.7
41	PTH-084 Endoscopic and Histological Activity as Predictors of Relapse in Patients Undergoing Surveillance Colonoscopy for Ulcerative Colitis. *Gut*, **2013**, 62, A245.2-A245	19.2
40	PTU-136 Prevalence of Functional Gastrointestinal Disorders in Consecutive New Patient Referrals to a Gastroenterology Clinic. *Gut*, **2013**, 62, A102.2-A103	19.2
39	PTH-194 A Retrospective Analysis of Glucose-Hydrogen Breath test for Small Intestine Bacterial Overgrowth in a Teaching Hospital. *Gut*, **2013**, 62, A290.2-A291	19.2
38	PWE-153 Association Between Constipation and Colorectal Cancer: Systematic Review and Meta-Analysis of Observational Studies. *Gut*, **2013**, 62, A193.2-A193	19.2
37	PTH-199 Prevalence of Organic Disorders in Consecutive New Patients Meeting Criteria for IBS in a Gastroenterology Clinic. *Gut*, **2013**, 62, A292.3-A293	19.2
36	Helicobacter pylori eradication. *Lancet, The*, **2011**, 378, 313; author reply 314	40

35	Coeliac disease and hypertransaminasaemia: a systematic review and meta-analysis. *Gut*, **2011**, 60, A18-A18	19.2
34	Predictors of response and loss of response to infliximab therapy for crohn's disease: a large UK single centre experience. *Gut*, **2011**, 60, A218-A218	19.2
33	Adverse events associated with infliximab therapy in a large single centre UK cohort. *Gut*, **2011**, 60, A217-A218	19.2
32	Granulocyte and monocyte adsorptive apheresis in the management of ulcerative colitis: authors reply. *Alimentary Pharmacology and Therapeutics*, **2011**, 33, 289-289	6.1
31	Potential role of granulocyte/monocyte adsorptive apheresis for ulcerative colitis with concomitant CMV infection: authors reply. *Alimentary Pharmacology and Therapeutics*, **2011**, 33, 498-498	6.1
30	Low yield of colonoscopy in individuals with suspected irritable bowel syndrome?. *American Journal of Gastroenterology*, **2010**, 105, 2508-9	0.7
29	Disease activity and venous thromboembolism in inflammatory bowel disease. *Lancet, The*, **2010**, 375, 1690; author reply 1690-1	40
28	Losses to follow-up limit conclusions regarding the efficacy of branched-chain amino acids in patients with hepatic encephalopathy. *American Journal of Gastroenterology*, **2011**, 106, 1718; author reply 1718-9	0.7
27	Response to Atreja et al.. *American Journal of Gastroenterology*, **2011**, 106, 2046	0.7
26	Response to Yang et al.. *American Journal of Gastroenterology*, **2011**, 106, 2044	0.7
25	Reply to Akobeng. *American Journal of Gastroenterology*, **2011**, 106, 1857-1858	0.7
24	Rome III criteria for functional gastrointestinal disorders: too much overlap to be useful?. *Gut*, **2011**, 60, A25-A25	19.2
23	Response to Doherty and Moss. *American Journal of Gastroenterology*, **2012**, 107, 487-488	0.7
22	Response to Kayhan et al.. *American Journal of Gastroenterology*, **2012**, 107, 321-322	0.7
21	OC-151 Prevalence of, and predictors of, a positive SEHCAT scan for bile acid diarrhoea in outpatients with chronic diarrhoea. *Gut*, **2012**, 61, A65.2-A65	19.2
20	PWE-059 Prevalence of gastro-esophageal reflux disease in individuals with irritable bowel syndrome: a systematic review and meta-analysis. *Gut*, **2012**, 61, A321.1-A321	19.2
19	PWE-060 Effect of gender on prevalence and subtype of irritable bowel syndrome: a systematic review and meta-analysis. *Gut*, **2012**, 61, A321.2-A321	19.2
18	PTU-055 Safety and tolerability of combination therapy for chronic hepatitis C: the Leeds experience. *Gut*, **2010**, 59, A71.1-A71	19.2

17	Balancing the risk of chronic gastrointestinal bleeding and thromboembolic events in a patient with a metallic aortic valve. *Clinical Medicine*, **2008**, 8, 461-2	1.9
16	Electronic Clinical Challenges and Images in GI. *Gastroenterology*, **2007**, 133, e3-e4	13.3
15	Efficacy of Senna and Magnesium Oxide for the Treatment of Chronic Idiopathic Constipation. *American Journal of Gastroenterology*, **2021**, 116, 1352-1353	0.7
14	Overlap Between Irritable Bowel Syndrome and Inflammatory Bowel Disease. *Gastroenterology and Hepatology*, **2020**, 16, 211-213	0.7
13	Dyspepsia: Ulcer and Non-Ulcer/Bloating and Early Satiety/Belching and Rumination22-25	
12	Bugs and the Brain in Inflammatory Bowel Disease: A Novel Treatment Target?. *Clinical Gastroenterology and Hepatology*, **2021**, 19, 1738-1739	6.9
11	Reply. *Clinical Gastroenterology and Hepatology*, **2016**, 14, 779	6.9
10	Letter: smoking as a modifiable risk factor for a complicated course in Crohn's disease. *Alimentary Pharmacology and Therapeutics*, **2016**, 43, 440	6.1
9	Letter: biologics are effective in neutralising the detrimental effect of smoking on the natural course of Crohn's disease - authors' reply. *Alimentary Pharmacology and Therapeutics*, **2016**, 43, 1246	6.1
8	Crohn's Disease Connectome Conundrums: Relevance to the Prevalence and Management of Mood Disorders. *Gastroenterology*, **2019**, 157, 1429-1430	13.3
7	Bloating and Abdominal Distention **2020**, 380-385	
6	Predictors of Dyspareunia Among Female Patients With Inflammatory Bowel Disease. *Clinical Gastroenterology and Hepatology*, **2020**, 18, 1000-1001	6.9
5	In the Face of Adversity: Is Resilience a New Target for Inflammatory Bowel Disease Therapy?. *Gastroenterology*, **2021**, 160, 466-467	13.3
4	Satiation or satiety? More than mere semantics - Authors' reply. *Lancet, The*, **2021**, 397, 1061	40
3	Reply. *Gastroenterology*, **2018**, 155, 1652-1653	13.3
2	Infliximab Therapeutic Drug Monitoring in Inflammatory Bowel Disease Virtual Biologics Clinic Leads to Durable Clinical Results. *Inflammatory Intestinal Diseases*, **2021**, 6, 132-139	2.5
1	Letter in response to Black et al. (2020): Authors' Reply.. *Neurogastroenterology and Motility*, **2022**, e14388	4